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Objectives: To investigate the therapeutic effects of repeated detrusor onabotulinumtoxinA (BoNT-A)
injections on autonomic dysreﬂexia (AD) in patients with chronic spinal cord injuries (SCI).
Materials and Methods: A total of 49 patients with SCI were enrolled to receive two sets of 200 U BoNT-A
injections into the detrusor at baseline and 6 months later. The primary end points were improvement in
the severity of AD and net change in the grade of incontinence. Secondary end points included net
changes in the scores of the Urogenital Distress Inventory (UDI-6), Incontinence Impact Questionnaire,
and quality of life index as well as urodynamic parameters.
Results: A total of 31 men and 18 women with cervical (n ¼ 27) or thoracic (n ¼ 22) SCI were enrolled.
They had a mean age of 41.6 years and duration of injury of 8 years. Fifteen patients did not have AD at
baseline or after treatment. AD was completely resolved in three patients, and improved in 18; treatment
made no difference in three patients and AD was exacerbated in 10. There were no signiﬁcant differences
in any urodynamic variables between patients with and without AD. A signiﬁcantly greater improvement
in the UDI-6 was noted in patients without AD and those in whom AD improved than in those with AD.
The occurrence of AD was also not signiﬁcantly associated with persistent urinary incontinence after the
BoNT-A injections. There was no signiﬁcant difference in the quality of life index between patients with
and without AD at the end point.
Conclusion: Detrusor BoNT-A injections improved AD in 62% of SCI patients with AD at baseline.
Copyright  2012, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Autonomic dysreﬂexia (AD) is a potentially life-threatening
condition. AD occurs most often in individuals with spinal cord
injuries (SCI) above the T6 level [1]. It is characterized by severe
paroxysmal hypertension (episodic high blood pressure) associated
with throbbing headaches, profuse sweating, nasal stufﬁness,
ﬂushing of the skin above the level of the lesion, bradycardia, and
apprehension and anxiety, which is sometimes accompanied by
cognitive impairment [2]. Patients with chronic SCI may develop
AD during bladder overdistention, stool impaction, or urinary tract
infection (UTI).artment of Urology, Buddhist
ang Road, Hualien, Taiwan.
ddhist Compassion Relief Tzu ChiStudies have shown that onabotulinumtoxinA (BoNT-A) injected
into the detrusor can restore urinary continence, lower the rate of
UTI, decrease intravesical pressure, and increase bladder compli-
ance in up to 80% of SCI patients [3,4]. Although repeated injections
of botulinum toxin A are necessary to achieve the desired effects,
most patients tolerate the procedure in exchange for a better
quality of life (QoL) [5]. Repeated injections restore renal function
or halt renal deterioration in patients with SCI [6].
BoNT-A has been proven to be effective for the treatment of
neurogenic detrusor overactivity (NDO) [7]. BoNT-A is one of the
most powerful neurotoxins; it inhibits the release of neurotrans-
mitters from the nerve ﬁbers and urothelium [8,9]. BoNT-A also has
an antinociceptive effect on the bladder wall. The current literature
also suggests that noxious (painful) stimuli are the primary initia-
tors of AD [10,11]. In previous studies, some patients with SCI and
detrusor sphincter dyssynergia (DSD) reported resolution or
improvement of AD after urethral or detrusor BoNT-A injections
[10,11]. However, other patients reported exacerbation or occur-
rence of AD after BoNT-A injections. No previous study appears toFoundation. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
The changes of autonomic dysreﬂexia in patients with spinal cord injury at baseline
and after onabotulinumtoxinA injections.
Male SCI Female SCI Total
No AD 10 (32.3%) 5 (27.8%) 15 (30.6%)
Complete resolution of AD 3 (9.7%) 0 (0.0%) 3 (6.1%)
Improvement of AD >50% 8 (25.8%) 7 (38.9%) 15 (30.6%)
Improvement of AD >25% 2 (6.5%) 1 (5.6%) 3 (6.1%)
No change of AD 2 (6.5%) 1 (5.6%) 3 (6.1%)
Exacerbation of AD 6 (19.4%) 4 (22.2%) 10 (20.4%)
AD ¼ autonomic dysreﬂexia; SCI ¼ spinal cord injury.
Table 2
The main symptom of autonomic dysreﬂexia at baseline and after onabotuli-
numtoxinA injections.
Baseline Post-treatment
Increase extremity reﬂex 8 9
Hypertension 5 4
Sweating 9 13
Flushing or erythema 4 2
Headache 6 3
Blurred vision 2 0
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injection.
In this study, we investigated the therapeutic effects of repeated
detrusor BoNT-A injections on urinary incontinence and AD in
patients with chronic SCI. We also investigated whether any factors
could predict the resolution or exacerbation of AD after BoNT-A
injections.
2. Materials and methods
Forty-nine patients with SCI and DSD were consecutively
enrolled in this prospective study and received two sets of 200 U
BoNT-A injections into the detrusor muscle at baseline and 6
months later. Patients were then monitored for therapeutic efﬁcacy
of the injections, which was evaluated by urinary incontinence and
an increase in bladder capacity. The effects of BoNT-A on AD were
also assessed at baseline and after repeat injection 6 months later.
All patients were aged 18 years or older and had a history of
chronic suprasacral SCI for 1 year or more. For all patients, the
diagnosis of DSD was made based on video urodynamic studies. In
addition, all patients voided by reﬂex or abdominal stimulation
with or without clean intermittent catheterization, were free of
indwelling catheters and cystostomy, and were free of UTI on
enrollment. All patients had been treated with antimuscarinic
agents for at least 1 year, which had failed to resolve the urinary
incontinence. Exclusion criteria included detrusor underactivity
and large bladder compliance, proven intrinsic sphincteric deﬁ-
ciency, Grade 2 or higher vesicoureteral reﬂux, and hypersensitivity
to BoNT-A or any type of botulinum toxin.
During the screening period and at each visit after BoNT-A
injection, patients were asked to report AD symptoms such as
hypertension, sweating, erythema in the upper extremities, head-
aches, and blurred vision during the last 3 months prior to the end
point. The severity of AD was also classiﬁed as mild, moderate, or
severe if the AD symptoms occurred occasionally, often, or
frequently, respectively.
This study was approved by the Institutional Review Board and
Ethics Committee of Tzu Chi General Hospital. Informed consent
was obtained before screening and all patients were informed
about the possible complications related to BoNT-A injections.
BoNT-A injection was performed in the operating room under
light intravenous general anesthesia. A total of 200 U of BoNT-A
(Allergan Co., Irvine, CA, USA) dissolved in 20 mL of normal saline
was injected into 40 sites in the detrusor muscle including the
lateral and posterior walls and the dome, sparing the trigone. The
injection sites were widely distributed to cover the whole bladder
wall. A 14F Foley catheter was routinely inserted after the BoNT-A
injections, and patients were discharged with catheter removal
the next morning and monitored in the outpatient clinic thereafter.
All patients were instructed to continue clean intermittent
catheterization or abdominal stimulation to empty their bladders.
BoNT-A injections were repeated 6 months later. Before each
subsequent set of BoNT-A injections, video urodynamic studies
were performed, during which AD was evaluated at full bladder or
when patients had a bladder reﬂex to void.
After BoNT-A injection, antimuscarinic agentswere discontinued.
Patients were monitored every 3 months for 12 months to gauge
improvements in urinary incontinence and AD. The urogenital
distress inventory (UDI-6) and the incontinence impact question-
naire (IIQ-7) [12] were used to assess incontinence distress and the
impact of urinary incontinence on daily life, respectively. In addition,
we extracted the three incontinence related scores (urgency, stress,
and insensible incontinence) from the UDI-6 to score the overall
incontinence grade. QoL was also evaluated using the QoL index
(QoL-I) self-assessment adapted from the International ProstaticSymptom Score [13]. The patient perception of bladder condition
questionnaire, a patient-reportedmeasure of bladder condition, was
used to assess patient satisfaction with the global treatment
outcome. Patient satisfaction was based on an improvement in the
patient perception of bladder condition by two or more points after
the second set of BoNT-A injections [14].
There were two primary end points: (1) improvement in the
severity of AD from baseline to 12months, and (2) net change in the
grade of incontinence from baseline to 12 months. Secondary end
points included net changes in the scores of the UDI-6, IIQ-7, and
QoL-I, as well as the changes in urodynamic parameters including
cystometric bladder capacity, voiding detrusor pressure at
maximum ﬂow rate (Qmax), postvoid residual volume, and bladder
compliance from baseline to 12 months.
All applicable institutional and governmental regulations
concerning the ethical use of human volunteers were followed
during the course of this research.
3. Results
A total of 31 men and 18 women with cervical (n ¼ 27) or
thoracic (n ¼ 22) SCI were enrolled. They ranged in age from 22
years to 74 years (mean, 41.6 years) and the duration of injury
ranged from 1 year to 35 years (mean, 8.0 years). At baseline, AD
was reported in 34 patients (21 men and 13 women). After two sets
of BoNT-A injections, AD was reported in 31 patients (18 men and
13women). Therewas no signiﬁcant difference in the occurrence of
AD between the cervical and thoracic levels or between genders.
Analysis of AD at baseline and after BoNT-A injections revealed
that 15 patients did not have AD at baseline or after treatment.
Complete resolution of AD was noted in three patients, improve-
ment in AD was noted in 18, and no difference in AD was found in
three patients, while exacerbation of AD occurred in 10 patients
(Table 1). The main symptoms of AD in these patients at baseline
and after BoNT-A injections are listed in Table 2.
Comparison of urodynamic parameters at baseline and after
BoNT-A injections showed no signiﬁcant difference in any urody-
namic variable between patients with and without AD, except that
patients with AD had a signiﬁcantly lower Qmax and larger post-
void residual volumes (Table 3) than patients without AD. There
were no signiﬁcant differences in the changes in urodynamic
Table 3
The urodynamics variables of patients with and without autonomic dysreﬂexia at
baseline and after onabotulinumtoxinA injections.
Baseline Non-AD (n ¼ 15) AD (n ¼ 34) p
CBC 215.1  104.7 276.3  160.2 0.130
Pdet 39.6  19.9 36.4  21.7 0.597
Qmax 7.45  6.13 3.78  4.53 0.020
Volume 97.9  81.9 78.6  115.7 0.513
PVR 117.3  73.9 197.7  122.4 0.010
Compliance 37.1  49.9 35.1  25.7 0.867
Post-treatment Non-AD (n ¼ 18) AD (n ¼ 31) p
CBC 392.0  185.7 379.1  176.3 0.851
Pdet 24.1  18.8 19.6  16.9 0.510
Qmax 4.40  5.28 0.82  2.17 0.064
Volume 75.0  83.7 18.1  47.4 0.068
PVR 317.0  170.6 360.9  195.0 0.545
Compliance 23.7  15.7 29.8  17.9 0.365
AD ¼ autonomic dysreﬂexia; CBC ¼ cystometric bladder capacity; Pdet ¼ detrusor
pressure ; PVR ¼ postvoid residual volume; Qmax ¼ maximum ﬂow rate.
Table 5




AD (n ¼ 21)
No improved
AD (n ¼ 13)
p
UDI-6 BL 13.8  2.66 11.67  3.50 9.10  3.54 0.035
12 mo 7.10  2.51* 7.75  3.98* 7.20  4.80
IIQ-7 BL 15.9  5.24 13.58  7.28 10.70  5.60 0.449
12 mo 6.10  5.32* 7.08  7.29* 5.30  5.66
QoL-I BL 4.50  1.27 4.92  1.08 4.10  1.60 0.704
12mo 1.90  1.29* 2.92  1.83* 2.20  1.55*
*p < 0.05 between baseline (BL) and 12 months.
AD ¼ autonomic dysreﬂexia; IIQ-7 ¼ incontinence impact questionnaire;
QoL-I ¼ quality of life index; UDI-6 ¼ urogenital distress inventory.
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and without improved AD (Table 4).
There were no signiﬁcant differences in the changes in the IIQ-7
and QoL-I from baseline to the end point among the three groups,
but a signiﬁcantly greater improvement in the UDI-6 was noted in
patients without AD and with improved AD than in patients
without improved AD (Table 5).
Among the 31 patients with AD at the end point, seven (23%)
had UTIs and four (13%) still had detrusor overactivity (DO). Among
the 18 patients without AD at the end point, eight (44%) had UTIs
and 10 (55%) had DO. There was no signiﬁcant difference in the
association of ADwith UTI or DO. The occurrence of ADwas also not
signiﬁcantly associated with persistent urinary incontinence after
BoNT-A injections.
Patients with persistent urinary incontinence had signiﬁcantly
lower QoL-I than those without urinary incontinence after the
BoNT-A injections (3.13  1.55 vs. 1.20  0.92, p ¼ 0.005). However,
there was no signiﬁcant difference in the QoL index between
patients with and without AD at the end point (1.94  1.52 vs.
2.00  2.83, p ¼ 0.962).
4. Discussion
The results of this study revealed that ADmay resolve, persist, or
exacerbate after detrusor BoNT-A injections in patients withTable 4
The changes of urodynamics variables among patients without AD, improved AD,
and no improved AD from baseline to end point.
No AD (n ¼ 15) Improved
AD (n ¼ 21)
No improved
AD (n ¼ 13)
p
CBC BL 177.5  95.0 251.1  117.62 230.7  104.4 0.366
12 mo 392  185.7* 363.1  186.6* 398.2  171*
Pdet BL 40.6  21.5 40.4  24.3 42.5  14.5 0.456
12 mo 24.1  18.8* 23.3 17.4* 15.3  16.3*
Qmax BL 7.60  6.48 3.83  4.90 5.50  5.42 0.582
12 mo 4.40  5.28* 1.08  2.61 0.50  1.58*
Volume BL 82.5  68.6 82.8  145.4 83.7  74.2 0.457
12 mo 75.0  83.7 24.8  57.8 10.2  32.3*
PVR BL 95.0  54.01 168.3  109.1 147.0  75.9 0.676
12 mo 317  170.6* 338.3  213.9* 388.0  177*
Compliance BL 19.5  22.8 33.8  25.6 29.2  29.3 0.755
12 mo 23.7  15.7 34.8  15.3 23.7  19.6
*p < 0.05 between baseline (BL) and 12 months.
AD ¼ autonomic dysreﬂexia; CBC ¼ cystometric bladder capacity; Pdet ¼ detrusor
pressure; PVR ¼ post void residual volume; Qmax ¼ maximum ﬂow rate.chronic SCI. Overall, 62% of the 34 patients with AD at baseline had
improvement in the severity of AD after BoNT-A injections.
Although AD was completely abolished in three patients, it was
exacerbated in 10 patients after detrusor BoNT-A injections.
AD is a potentially life-threatening condition that is considered
a medical emergency requiring immediate attention. It is believed
to be triggered by cutaneous or visceral afferent stimuli that
originate below the level of the spinal cord lesion [1]. The most
common causes of AD are bladder distention and stool impaction.
UTI can also trigger AD, regardless of whether there is an
indwelling catheter. In spinal cord transection, these afferent
impulses are unable to travel past the injury, resulting in an
enhanced spinal cord reﬂex to the autonomic nervous system in
response to stimuli. It is believed that these afferent stimuli trigger
and maintain an increase in blood pressure via sympathetically
mediated vasoconstriction in the muscle, skin, and splanchnic
vascular beds [15].
Previous treatments of AD included removal of triggering
stimuli and administration of antihypertensive or vasodilator
agents. In clinical trials of detrusor BoNT-A for treatment of NDO,
decreased severity and abolishment of AD were observed and
reported [10,11]. This study conﬁrmed that the severity of AD could
be reduced after detrusor BoNT-A injections in 62% of SCI patients
with NDO. Although some patients might have AD exacerbation,
this novel treatment could be applied for treatment of patients with
severe AD that affects QoL.
Recent research suggests that noxious stimuli are the primary
initiators of AD, and that AD induced by noxious stimulation
increases with time after SCI. However, Burton et al found that
activation of pain receptors in muscle and skin below the lesion in
individuals with SCI did not trigger AD [9]. They suggested that not
all noxious stimuli trigger AD, and some non-noxious stimuli also
trigger it. It is important to consider non-noxious sources of stim-
ulation in addition to noxious triggers. Detrusor injection of BoNT-A
induces trauma to the bladder wall, causing acute inﬂammation in
the suburothelial nerve plexus. These noxious stimuli from the
bladder wall might result in activation of the autonomic nervous
system and exacerbate AD in the acute stage of detrusor BoNT-A
injections.
Botulinum toxin A modulates afferent activity of the bladder in
association with reduced DO and overactive bladder symptoms in
NDO patients [16]. In a chronic SCI rat model, intravesical BoNT-A
signiﬁcantly inhibited the afferent response without impairing
efferent bladder function [17]. A clinical study has suggested that
BoNT-A has an antinociceptive effect on bladder afferent pathways
in patients with neurogenic detrusor overactivity, producing both
symptomatic and functional improvements [8].
The results of this study provide evidence that AD can be reduced
in the majority of patients after detrusor BoNT-A injections, sug-
gesting the antinociceptive response to BoNT-A in the bladder wall
might have an effect on the spinal cord by blocking the transmission
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treatment in rats also signiﬁcantly blocked the dysreﬂexia response
(high arterial pressure with bradycardia) induced by cystometry
after spinal cord transection. Intravesical BoNT-A also signiﬁcantly
lowered nerve growth factor concentrations in the bladder and the
T4 dorsal root ganglion segment [18]. These results suggest that
BoNT-A treatment modulated sensory and motor transmission, as
well as reduced inﬂammatory conditions in the bladder and spinal
cord. It is also possible that the chronic symptomatology of bladder
hypersensitivity is due to central sensitization and persistent
abnormality or activation of the afferent sensory system [19]. In this
regard, inhibition of neuroplasticity of the sensory ﬁbers in the
suburothelial space by BoNT-A injections into the detrusor muscle
could be a therapeutic target to reduce the severity of AD in patients
with chronic SCI.
We failed to identify any predictive factors for the reduction
or exacerbation of AD after BoNT-A injection into the detrusor.
There was no signiﬁcant difference in the baseline or post-
treatment urodynamic variables among patients without AD,
with improved AD, and with exacerbated AD. The incidence of UTI
and persistent DO after BoNT-A injection were also similar among
groups. Additionally, the level of SCI and the duration of SCI did not
signiﬁcantly differ among groups. Recent evidence suggests that
the urothelium plays a prominent role in modulating bladder
sensory nerve ending excitability. It is conceivable that factors and
processes affecting the plasticity of bladder neurons after SCI
may be partly due to changes occurring in the urothelium. In early
SCI, disruption to bladder uroepithelial integrity results in
increased permeability of the urothelium to urine and urine-borne
substances, resulting in cystitis or inﬂammation of the bladder
[20]. These urothelial changes and signiﬁcant deﬁcits in tight
junction proteins could be detected in chronic SCI, suggesting that
early pathological changes to the bladder continue throughout the
chronic phase of injury. Whether SCI patients with AD have greater
inﬂammation in their bladder walls and dorsal root ganglia than
those without AD has not been elucidated. It is possible that
BoNT-A detrusor injections have a reductive effect on chronic
inﬂammation in the bladder wall as well as the spinal cord and
result in improvement in the severity of AD. AD might not be
eradicated in patients with severe inﬂammation in the bladder
wall after inadequate dosing of BoNT-A.
Interestingly, we found that the presence of AD did not inﬂuence
the patient’s perception of QoL. Nonetheless, patients with persis-
tent urinary incontinence had lower QoL indices compared with
those without AD or urinary incontinence. Thus, most SCI patients
tolerated AD, but not urinary incontinence, after detrusor BoNT-A
injection therapy.
The limitations of this study included the small patient number
and lack of a control arm to demonstrate that AD was induced by
BoNT-A but not by the injection technique.5. Conclusion
This study revealed that detrusor BoNT-A injections improved
AD in themajority of SCI patients with AD at baseline, while ADwas
exacerbated in some patients after detrusor BoNT-A injectiontherapy. A higher dose of BoNT-A or a longer treatment period
might result in better outcomes.References
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